CHO Cell Line Development Services
As targeted therapies using biopharmaceuticals are becoming more critical, manufacturing processes that speed up their production efficiently, robustly, and cost-effectively gain more importance in order to support patients globally.
Chitose laboratory’s mission is to create the next-generation biopharmaceutical manufacturing platform centering on our proprietary and uniquely high-performance CHO cells (known as CHO-MK cells), which is reliably applicable to accelerate the development of biopharmaceuticals, reduce the manufacturing costs and contribute to global health care.
CHO-MK cell performance
CHO-MK*) host cell line which is banked as a host cell bank for the production of biopharmaceuticals, is our CHO host cell line developed from the primary cell culture of a healthy Chinese hamster ovary tissue for industrial applications. CHO-MK has demonstrated remarkably higher productivity when compared to the conventional CHO host cell lines.
*)CHO-MK cells were developed under the support of AMED (Grant Number JP18ae101054)
High Performance
- Large amount of antibody production
(10 g/L) in 5 days
CHO-MK Host Cell Bank
- Applicable for biopharmaceutical production
- Conditioned to complete serum-free suspension culture
- Passed viral safety tests
- Completed Host Cell Bank testing package (CoA)
Benefits of CS CHO Vector
- Chitose Laboratory’s original expression vector system
- Signal nucleotide sequences for high expression utility
- Expert in the design of nucleotide sequences for high expression in CHO-MK cells
CLD Platform
- CHO-MK Cell Line and CS CHO expression vector system
- FCM-based enrichment of highly producing stable pools
- High-fidelity cloning by single-cell sorting
- Clonality assurance by high-resolution imaging
- Early process development using bioreactor
